The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs

Biological Psychiatry
Pau CeladaFrancesc Artigas

Abstract

Perceptual and psychic alterations and thought disorder are fundamental elements of schizophrenia symptoms, a pathology associated with an abnormal macro- and microcircuitry of several brain areas including the prefrontal cortex (PFC). Alterations in information processing in PFC may partly underlie schizophrenia symptoms. The 5-HT(2A/2C) agonist DOI and antipsychotic drugs were administered to anesthetized rats. Single unit and local field potential (LFP) extracellular recordings were made in medial PFC (mPFC). Electrolytic lesions were performed in the thalamic nuclei. DOI markedly disrupts cellular and network activity in rat PFC. DOI altered pyramidal discharge in mPFC (39% excited, 27% inhibited, 34% unaffected; n = 51). In all instances, DOI concurrently reduced low-frequency oscillations (.3-4 Hz; power spectrum: .25 +/- .02 and .14 +/- .01 microV(2) in basal conditions and after 50-300 microg/kg intravenous (i.v.) DOI, respectively; n = 51). Moreover, DOI disrupted the temporal association between the active phase of LFP and pyramidal discharge. Both effects were reversed by M100907 (5-HT(2A) receptor antagonist) and were not attenuated by thalamic lesions, supporting an intracortical origin of the effects of DOI. The r...Continue Reading

References

Jul 9, 1991·European Journal of Pharmacology·J C GarrattC A Marsden
Sep 1, 1988·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A Carlsson
Oct 29, 1993·Science·M SteriadeT J Sejnowski
Aug 20, 1996·Proceedings of the National Academy of Sciences of the United States of America·M LaruelleR B Innis
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Jan 1, 1997·Neuroscience·D Contreras, M Steriade
Jan 1, 1997·Journal of Psychopharmacology·H J GroenewegenH B Uylings
Oct 27, 1997·Annals of Internal Medicine·V Fuster, I S Nash
Feb 7, 1998·Current Opinion in Neurobiology·M F Egan, D R Weinberger
Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt
May 22, 1998·Archives of General Psychiatry·M S KeshavanD J Kupfer
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J W NewcomerJ W Olney
Jan 23, 1999·Biological Psychiatry·L D Selemon, P S Goldman-Rakic
Nov 24, 1999·Archives of General Psychiatry·J S KwonR W McCarley
Apr 27, 2000·Acta Psychiatrica Scandinavica·D BegićN Jokić-Begić
Oct 4, 2000·Nature Neuroscience·M V Sanchez-Vives, D A McCormick
Dec 6, 2000·Progress in Brain Research·H J Groenewegen, H B Uylings
Jan 4, 2001·Cell Death and Differentiation·P BangsK White
Jan 6, 2001·Neuron·D A Lewis, J A Lieberman
Jan 1, 1990·Behavioural Pharmacology·B.A. Ellenbroek, A.R. Cools
Mar 20, 2001·Critical Reviews in Neurobiology·B Elvevåg, T E Goldberg
Apr 3, 2001·Annual Review of Neuroscience·E K Miller, J D Cohen
Nov 3, 2001·Science·R StickgoldM Fosse
Dec 18, 2001·Biological Psychiatry·D R WeinbergerT E Goldberg
Feb 6, 2004·Pharmacology & Therapeutics·David E Nichols

❮ Previous
Next ❯

Citations

Dec 17, 2008·Neurotoxicity Research·Lucila KargiemanFrancesc Artigas
Jul 31, 2012·Psychopharmacology·José L MorenoJavier González-Maeso
Nov 15, 2011·Molecular Neurobiology·M Victoria Puig, Allan T Gulledge
Oct 21, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lucila KargiemanPau Celada
Apr 8, 2014·Neuropharmacology·David A MartinCharles D Nichols
Feb 20, 2016·Neuroscience and Biobehavioral Reviews·Susana Aznar, Mona El-Sayed Hervig
Feb 5, 2016·Pharmacological Reviews·David E Nichols
Jan 20, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L Lladó-PelfortP Celada
Oct 1, 2011·Revista de psiquiatrí́a y salud mental·Francesc Artigas
Mar 10, 2009·Trends in Neurosciences·Javier González-Maeso, Stuart C Sealfon
Oct 27, 2015·Frontiers in Pharmacology·Gongliang Zhang, Robert W Stackman
Jul 21, 2014·Biological Psychiatry·Eva Troyano-RodriguezFrancesc Artigas
May 29, 2009·The European Journal of Neuroscience·H-P Landolt, R Wehrle
Apr 18, 2013·Synapse·Ronald M Salomon, Ronald L Cowan
Jan 12, 2010·Acta Psychiatrica Scandinavica·F Artigas
Mar 30, 2016·Neuropharmacology·Adam L HalberstadtJared W Young
Apr 14, 2016·Proceedings of the National Academy of Sciences of the United States of America·Robin L Carhart-HarrisDavid J Nutt
Apr 18, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Alberto FernándezJuan José López-Ibor
Jan 22, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Bill P GodsilThérèse M Jay
Apr 18, 2016·Current Biology : CB·Enzo TagliazucchiRobin Carhart-Harris
Apr 18, 2016·Neuropharmacology·Marcello VenziGiuseppe Di Giovanni
Mar 24, 2015·ACS Chemical Neuroscience·M Victoria Puig, Thomas Gener
Aug 1, 2014·Behavioural Brain Research·Elizabeth P Bauer
Mar 22, 2014·The International Journal of Neuropsychopharmacology·Maurizio S RigaPau Celada
Jun 12, 2013·The International Journal of Neuropsychopharmacology·José L Moreno, Javier González-Maeso
Jul 3, 2013·The International Journal of Neuropsychopharmacology·Pau CeladaFrancesc Artigas
Nov 6, 2018·Current Opinion in Psychiatry·Robin L Carhart-Harris
Jun 22, 2019·Pharmacological Reviews·R L Carhart-Harris, K J Friston
Mar 20, 2013·Molecular Pharmacology·Mitsumasa KuritaJavier González-Maeso
Oct 17, 2017·Scientific Reports·Robin L Carhart-HarrisDavid J Nutt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here